Beigene Ltd (NASDAQ:BGNE) CMO Jane Huang sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $134.74, for a total value of $336,850.00. Following the completion of the sale, the chief marketing officer now directly owns 328,873 shares in the company, valued at approximately $44,312,348.02. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Jane Huang also recently made the following trade(s):
- On Monday, July 29th, Jane Huang sold 10,130 shares of Beigene stock. The stock was sold at an average price of $134.54, for a total value of $1,362,890.20.
- On Thursday, June 27th, Jane Huang sold 430 shares of Beigene stock. The stock was sold at an average price of $124.52, for a total value of $53,543.60.
- On Monday, May 20th, Jane Huang sold 300 shares of Beigene stock. The stock was sold at an average price of $130.12, for a total value of $39,036.00.
Shares of BGNE stock opened at $141.19 on Friday. The stock has a 50 day moving average of $129.48 and a two-hundred day moving average of $129.91. The company has a current ratio of 6.46, a quick ratio of 7.47 and a debt-to-equity ratio of 0.15. Beigene Ltd has a 12 month low of $105.19 and a 12 month high of $182.30.
Beigene (NASDAQ:BGNE) last posted its earnings results on Thursday, August 8th. The company reported ($1.43) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($3.01) by $1.58. The business had revenue of $243.35 million during the quarter, compared to the consensus estimate of $65.58 million. Beigene had a negative return on equity of 38.41% and a negative net margin of 153.32%. Beigene’s revenue was up 360.8% on a year-over-year basis. During the same quarter last year, the company earned ($2.92) EPS. On average, equities analysts anticipate that Beigene Ltd will post -12.27 earnings per share for the current fiscal year.
BGNE has been the subject of a number of research reports. Piper Jaffray Companies reiterated a “buy” rating on shares of Beigene in a research report on Thursday, June 20th. Macquarie initiated coverage on Beigene in a research report on Friday, July 5th. They issued an “underperform” rating for the company. ValuEngine upgraded Beigene from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Maxim Group set a $170.00 price objective on Beigene and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, Cowen reiterated a “buy” rating and issued a $170.00 price objective on shares of Beigene in a research report on Friday, May 31st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $181.28.
Several institutional investors have recently bought and sold shares of the stock. Riverhead Capital Management LLC lifted its position in shares of Beigene by 28.6% during the 2nd quarter. Riverhead Capital Management LLC now owns 450 shares of the company’s stock worth $56,000 after buying an additional 100 shares during the period. IFM Investors Pty Ltd lifted its position in shares of Beigene by 6.9% during the 2nd quarter. IFM Investors Pty Ltd now owns 1,949 shares of the company’s stock worth $242,000 after buying an additional 126 shares during the period. Nissay Asset Management Corp Japan ADV lifted its position in shares of Beigene by 4.8% during the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 2,753 shares of the company’s stock worth $363,000 after buying an additional 127 shares during the period. Comerica Bank lifted its position in shares of Beigene by 3.5% during the 1st quarter. Comerica Bank now owns 4,365 shares of the company’s stock worth $638,000 after buying an additional 146 shares during the period. Finally, Capital Investment Advisory Services LLC bought a new position in shares of Beigene during the 2nd quarter worth approximately $26,000.
Beigene Company Profile
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Featured Article: Economic Bubble
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.